Incyte to Report Second Quarter Financial Results
The schedule for the press release and conference call/webcast is as follows:
-
Q2 2026 Press Release:
July 28, 2026 , at7:00 a.m. ET -
Q2 2026 Conference Call:
July 28, 2026 , at8:00 a.m. ET - Domestic Dial-In Number: 877-407-3042
- International Dial-In Number: 201-389-0864
- Conference ID Number: 13759527
If you are unable to participate, a replay of the conference will be available for thirty days. The replay dial-in number for the
A live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.
About Incyte
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.
To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260708563739/en/
Incyte Contacts
Media
media@incyte.com
Investors
ir@incyte.com
Source: Incyte